PAULA · INTEL
High Denial RiskRevenue at Risk: $643K–$1.3M (est)Effective Oct 1, 2028 · CMS-1849-P

New AI Service Pathway Creates Reimbursement Opportunity — and Audit Exposure

CMS displayed the FY 2027 IPPS proposed rule (CMS-1849-P) on April 10, 2026, proposing to repeal the alternative NTAP pathway for FDA Breakthrough Device-designated products beginning FY 2028. All AI devices would need to meet the full three-criteria standard — newness, cost adequacy, AND substantial clinical improvement — eliminating the 'fast track' that allowed AI devices to bypass the clinical improvement standard. Comments due June 9, 2026.

Published by the PAULA Intelligence TeamReviewed by a board-certified Physician Advisor
Affected Payers
  • · Medicare FFS
  • · Medicare Advantage
  • · Commercial
  • · Medicaid MCO
Service Lines
  • · Medical Necessity
  • · Experimental / Investigational
  • · DRG Validation
  • · Prior Auth
01 — Signal

Why PAULA flagged this

CMS-1849-P opens or closes the reimbursement pathway for AI-enabled services: it directly affects which AI tools can be billed and how denial risk maps to coverage policy. CMS cited concerns about a 'limited evaluation process' for AI-based breakthrough devices and overreliance on expedited pathways, signaling a materially higher evidentiary bar for AI diagnostic and therapeutic devices seeking inpatient Medicare reimbursement add-ons. CMS also proposes to repeal the analogous alternative pathway under OPPS pass-through payments.

Recommended Action — This Week

Confirm coding pathway and documentation requirements with revenue cycle before billing the new service. Inventory every AI device with an active NTAP or OPPS pass-through approval, map each to its approval FY and pathway (alternative Breakthrough vs. full three-criteria), and stand up a tracking dashboard in CLAIR before the FY 2028 effective date.

Locked · Full Brief

Scenarios, defenses, P2P scripts, executive lenses, and payer impact unlock with any briefing tier.

02 — Full Analysis

What CMS-1849-P would change for AI device reimbursement

03 — Denial Scenarios PAULA is Watching

Three high-probability denial patterns

PAULA inference based on payer behavior patterns and the source rule's structure — not directly quoted in the regulatory text. Verify against current payer policy before citing in an appeal.

Scenario · 01

NTAP Add-On Charge Denial — AI Device Breakthrough Pathway Lapse Post-FY 2028

Payer Argument

(Inferred) MA plan or RAC auditor identifies an inpatient claim with an NTAP add-on for an AI-enabled sepsis prediction or stroke detection device. Payer argues that as of FY 2028, the device's NTAP approval was granted under the now-repealed alternative Breakthrough Device pathway and does not meet the full three-criteria standard. Payer denies the incremental NTAP add-on payment in full.

Defense

UR and CDI leadership must audit all active NTAP-approved AI devices. For each device, document the NTAP approval FY and pathway, the sunset date, and whether the manufacturer has filed for a full three-criteria NTAP application for FY 2028+. Build a tracking dashboard in CLAIR. For already-billed claims, verify NTAP approval was valid at date of service before responding to any RAC or MA audit.

P2P Framing

'The AI device used in this case held a valid NTAP approval under CMS guidelines in effect at the date of service. CMS-1849-P is a proposed rule with a prospective effective date of FY 2028 (October 1, 2027) and cannot be retroactively applied to FY 2026 or FY 2027 dates of service. We request the payer cite the specific regulatory basis for retroactive application of a proposed, not-yet-finalized rule.'

Scenario · 02

Experimental/Investigational Denial — AI Diagnostic Lacking Clinical Improvement Evidence

Payer Argument

(Inferred) Commercial payer or MA plan audits an inpatient case involving AI-enabled imaging interpretation. Payer cites CMS-1849-P's stated concern about 'limited evaluation process' and the absence of demonstrated substantial clinical improvement to deny the AI-assisted component of care as experimental or investigational. Payer may attempt to reduce the entire MS-DRG payment or deny a facility fee component tied to the AI service.

Defense

Establish a standardized AI device use attestation block in the EHR for all inpatient cases involving NTAP-eligible AI tools, capturing AI device name and FDA designation, the specific clinical finding generated, how the finding influenced decision-making, and treating physician attestation that AI output was reviewed and acted upon. Embed in radiology, neurology, and critical care note templates before FY 2028.

P2P Framing

'The AI device used in this case carries FDA Breakthrough Device designation. Its NTAP approval, in effect at the date of service, was granted by CMS following review of the manufacturer's evidence submission. CMS-1849-P's concerns about the evidentiary standard are prospective policy proposals — they do not retroactively reclassify a device approved under prior-year NTAP criteria as experimental or investigational.'

Scenario · 03

DRG Validation & NTAP Recoupment — Cost Adequacy and MS-DRG Mismatch Scrutiny

Payer Argument

(Inferred) RAC or MAC auditor reviews an inpatient claim where an AI-enabled therapeutic or diagnostic device generated an NTAP add-on. Auditor argues either that the AI device's costs are not adequately separable from the base MS-DRG, or that the MS-DRG does not reflect the AI device's incremental resource use. Payer pursues recoupment on grounds that the case did not exceed the cost threshold required for NTAP eligibility.

Defense

Finance and CDI must establish a dedicated charge-capture workflow for every AI-enabled device with active NTAP approval: distinct revenue code or HCPCS placeholder in the charge master, per-case device costs itemized on the UB-04, manufacturer NTAP cost-adequacy evidence on file, and quarterly internal audits comparing billed NTAP add-on amounts against actual per-case device cost data.

P2P Framing

'The NTAP add-on claimed in this case reflects documented per-case device costs that exceed the applicable MS-DRG payment threshold, consistent with the cost-adequacy criterion satisfied in the device's CMS NTAP approval. We can provide the itemized charge detail and the CMS NTAP approval letter upon request. CMS-1849-P's proposed prospective changes do not affect the validity of this FY 2027 claim.'

04 — Decision Layer

Three executive lenses

Physician Advisor

In P2P reviews involving AI device NTAP denials, anchor on the three-criteria standard as it applies to the claim's fiscal year. Lead with the specific outcome metric the AI device improves (earlier sepsis detection reducing ICU days, AI stroke triage reducing door-to-needle time), cite peer-reviewed publications or FDA clinical submission data, and distinguish between 'limited evaluation' as a CMS preamble concern versus the actual clinical evidence for the specific device. Flag to payer medical directors that applying proposed-rule rationale to finalized-FY claims exposes the payer to bad-faith denial liability.

CFO / Revenue Cycle

Each denied NTAP claim represents the add-on payment of up to 65% of costs above the MS-DRG threshold — $1,000 to $20,000+ per case depending on device cost. Immediately inventory all AI devices currently receiving NTAP or OPPS pass-through payments, quantify annualized NTAP revenue per device, and model full-repeal impact post-October 2028. Configure CLIP charge capture and denial management modules to flag AI device charges, auto-attach NTAP documentation packets, and track denial rates by device and payer. Engage the CMS comment process before June 9, 2026.

Compliance & Legal

CLAIR should classify this as a Tier 1 Proposed Rule with High Finalization Probability. Establish an NTAP device registry mapping each device to FDA designation, CMS approval FY, clinical evidence file, and charge codes. Build a rule-finalization trigger that automatically initiates a coverage-strategy review. Implement a pre-submission checklist requiring physician attestation of clinical improvement evidence before any AI device NTAP claim is filed — creating a defensible audit trail under any future OIG review and minimizing False Claims Act exposure.

05 — Denial Playbook

Appeal phrasing, levers & citations

06 — Payer Impact

Projected payer behavior

PAULA watch item — projected payer behavior under this rule. Verify against current payer medical policy or provider bulletin.

Medicare FFS
High

Direct loss of NTAP incremental reimbursement (up to 65% of cost above DRG threshold) for AI devices that relied solely on Breakthrough Device designation to qualify.

Medicare Advantage
High

MA plans may preemptively restrict AI device reimbursement, increasing prior auth denials and medical necessity denials for AI-assisted inpatient services.

Commercial
Medium

Revenue impact depends on contract terms, but increased experimental/investigational denials for AI devices are likely — particularly for recently FDA-cleared AI diagnostics without robust RCT data.

Medicaid MCO
Low–Medium

Indirect risk; primary concern is CMS rationale cascading into Medicaid managed care coverage policies, reducing reimbursement for AI-assisted inpatient services not yet proven in Medicaid populations.

Underwriter Read · Pathway Risk Artifact

How this brief lands across the affected payment pathways

Composed from PAULA's internal Underwriter / CFO intelligence corpus. Each pathway is scored on a five-signal frame — loss frequency, loss severity, signal quality, regulatory volatility, and denial-risk index.

Pathway 3 · IPPS add-on

NTAP — New Technology Add-on Payment Under IPPS

High · 3.9Viability · Conditional

Direct add-on payment above MS-DRG for qualifying new technology, but time-limited (2–3 years). FY 2027 IPPS Proposed Rule (CMS-1849-P) proposes eliminating the alternative NTAP pathway used by most AI applicants. Treat as bridge funding.

3
Loss Freq
4
Loss Sev
3
Signal Qual
5
Reg Volatility
4
Denial Risk
Top scenario · Humana MA LTACH Denial — Post-Acute Analytics Trigger — $5.2M revenue at risk
Pathway 2 · OPPS / SaaS

HCPCS Level II Codes and OPPS New Technology APCs

Moderate · 2.4Viability · High

Strongest direct payment mechanism for AI SaaS in hospital outpatient settings. 19 HCPCS codes assigned to AI services as of April 2026; CMS continues to add new-tech APCs annually. Clearest path to a separately reimbursable AI service line in OPPS.

2
Loss Freq
3
Loss Sev
4
Signal Qual
3
Reg Volatility
2
Denial Risk
Top scenario · G2211 Add-On Denial — Insufficient Documentation — $1.1M revenue at risk
Source intelligence held internally · Not distributed as a standalone PDF
Operationalize this brief

Choose your briefing tier.

One-time purchase · Delivered as a downloadable executive PDF with citations and CLIP-ready operational templates.

Assess your exposure
Sources: FY 2027 IPPS Proposed Rule (CMS-1849-P), published April 14, 2026 · 42 C.F.R. § 412.87 (IPPS NTAP) · 42 C.F.R. § 419.66 (OPPS pass-through). Source Confidence: MEDIUM — Proposed rule, not yet finalized. Locate the underlying Federal Register notice before formal use.
PAULA · Clinefficiency Pro — Real-time decision intelligence for UM, denial risk, and regulatory change.